PUBLISHER: Inkwood Research | PRODUCT CODE: 1268540
PUBLISHER: Inkwood Research | PRODUCT CODE: 1268540
The Asia-Pacific dry eye disease market is set to register a CAGR of 5.60% during the forecast period, 2023-2032. The key growth drivers include the increasing number of ophthalmologists in countries such as India, China, and Japan, in addition to the rising ophthalmic education programs and initiatives for improved eye health.
Australia & New Zealand, India, Japan, Indonesia, China, South Korea, Thailand, and Rest of Asia-Pacific are evaluated for the Asia-Pacific dry eye disease market growth assessment. Dry eye disease (DED) is the most common ocular disease observed in South Korea. As per the research article published in 2019 in the Korean Journal of Family Medicine, female sex, suicidal ideation, a history of cataracts, and hypercholesterolemia are likely to be the risk factors for dry eye symptoms among elderly Koreans. Besides, the country records a rapidly increasing aging population, as well.
On the other hand, as per the survey conducted by Johnson & Johnson Vision in 2019, the majority of people in Thailand, accounting for 77%, frequently suffer from symptoms of Meibomian Gland Dysfunction (MGD) a major cause for dry eye disease. However, while 79% of Thais are not familiar with MGD, 69% choose not to seek medical and professional help, thus, risking their eyesight. Hence, these factors are expected to fuel the dry eye disease market growth in the Asia-Pacific over the forecasting years.
Key companies operating in the market are Otsuka Holdings Co Ltd, Santen Pharmaceutical Co Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, etc.